|Bid||151.60 x 1100|
|Ask||164.39 x 900|
|Day's range||162.27 - 171.10|
|52-week range||80.43 - 219.85|
|Beta (5Y monthly)||0.75|
|PE ratio (TTM)||868.00|
|Earnings date||29 Apr 2020 - 03 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||187.69|
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® DASH Insulin Management System (Omnipod DASH™ System), announced today that the Company’s Omnipod DASH™ System has been named the 2020 Product of the Year in the Health Systems category. Product of the Year is the largest consumer-voted award for product innovation with 40,000 U.S. consumers surveyed.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that it plans to pause the pivotal study of the Omnipod Horizon™ Automated Glucose Control System to correct a software anomaly. The identified anomaly could result in the system using an incorrect glucose value which has the potential to impact insulin delivery. The issue is rare, but because of the potential to affect insulin delivery, the Company will pause the study until the anomaly is corrected. No adverse events have been reported due to this issue.
Insulet (PODD) delivered earnings and revenue surprises of -11.11% and 5.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months and full year ended December 31, 2019.
Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at four upcoming investor conferences (all times below are in Eastern Time):
This agreement is a major step forward in Insulet's (PODD) commitment toward bolstering its automated insulin delivery system and providing better clinical outcomes for diabetes patients.
Dexcom and Insulet Announce Commercial Agreement
Today we'll evaluate Insulet Corporation (NASDAQ:PODD) to determine whether it could have potential as an investment...
The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.
The full-market commercial launch of Insulet's (PODD) Omnipod DISPLAY and Omnipod VIEW apps for use with the Omnipod DASH System is encouraging.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
With digital diabetes management space rapidly gaining momentum, patients with diabetes can look forward to better and improved outcomes.
Insulin pump maker Insulet continues to move toward a 187.35 buy point from a shallow cup base. It's already in buy range from a rebound of a 50-day/10-week line.